Antiplatelet therapy is indicated in patients with non-cardioembolic stroke. The clinically
used antiplatelet agents for secondary stroke prevention in this group of patients include the …

Background: Stroke risk is heightened among patients who have had a primary stroke or
transient ischaemic attack (TIA). The primary care physician is in the best position to monitor …

Opinion statement In patients with transient ischemic attack (TIA) or ischemic stroke of
noncardiac origin, antiplatelet drugs are able to decrease the risk of stroke by 11% to 15 …

Antiplatelet therapy has become the mainstay of secondary stroke prevention. Recurrence
risk after transient ischemic attack (TIA) or ischemic stroke ranges from 5% to 20% per year …

Recurrence risk after transient ischemic attack (TIA) or ischemic stroke (IS) ranges from 5 to
20% per year [1–3]. The risk is highest immediately after the first event [4–6]. Numerous trials …

The most effective approach to secondary prevention depends on the cause of the first
ischemic stroke. Patients at high risk for recurrent cardioembolic stroke (ie, those with atrial …

Background and Purpose Given the high risk of stroke after TIA (transient ischemia attack) or
stroke and the adverse reaction of bleeding of antiplatelets, we undertook a meta-analysis …

Antiplatelet drugs have an established efficacy in the secondary prevention of ischemic
stroke. The recent results of the CAPRIE, CURE, and CREDO studies formed the rationale …

Antiplatelet therapy is universally recommended for the prevention of recurrent events in
patients with noncardioembolic ischaemic stroke or transient ischaemic attack (TIA), acute …

Stroke exacts a huge toll physically, mentally and economically. Antiplatelet therapy is the
cornerstone of secondary stroke prevention, and proven drugs available to successfully …